Co-Authors
This is a "connection" page, showing publications co-authored by Nicholas Kennedy and Peter Irving.
Connection Strength
1.193
-
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021 10; 70(10):1884-1893.
Score: 0.235
-
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021 05; 70(5):865-875.
Score: 0.234
-
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. Frontline Gastroenterol. 2020; 11(5):343-350.
Score: 0.222
-
Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut. 2020 10; 69(10):1769-1777.
Score: 0.222
-
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020 06; 69(6):984-990.
Score: 0.219
-
Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients. J Crohns Colitis. 2021 Sep 02.
Score: 0.060